Fast Five Quiz: Heart Failure Comorbidities

Ioana Dumitru, MD


July 15, 2021

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the first class of glucose-lowering agents associated with a reduced risk for HF in patients with diabetes and a reduced risk for hospitalization owing to HF.

The prevalence of diabetes is similar in HFpEF and HFrEF because the two disorders overlap; diabetes is present in up to 45% of patients with chronic HF, regardless of whether they have reduced or preserved ejection fraction.

In terms of prevalence and its association with clinical outcome, renal dysfunction may be the most important comorbidity in HF. The condition is common with renin-angiotensin-aldosterone system–inhibiting therapy, which is used in most patients with HF. With no evidence-based therapy for these comorbidities, morbidity and mortality in patients with HF and renal dysfunction remains an underappreciated topic.

Available data suggest that intensive glycemic control in patients with diabetes does not lessen the risk for HF.

Learn more about type 2 diabetes treatment and management.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.